Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 1 | Biomarker Research

Figure 1

From: Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib

Figure 1

Molecular responses in patients with imatinib-resistant and imatinib-intolerant CML treated with nilotinib. The molecular response was evaluated according to the international scale of standardized quantitative real-time polymerase chain reaction at the beginning of the study and every 3 months thereafter. The X-axis shows the time-point and patient number for molecular response evaluation. The Y-axis shows the percentage of patients who achieved a molecular response.

Back to article page